Zacks Investment Research Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell

Zacks Investment Research cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports.

According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “

Several other brokerages also recently weighed in on CRVS. Jefferies Financial Group initiated coverage on shares of Corvus Pharmaceuticals in a report on Wednesday, December 1st. They issued a buy rating and a $8.00 target price on the stock. Cantor Fitzgerald boosted their price objective on shares of Corvus Pharmaceuticals from $5.00 to $8.00 and gave the stock an overweight rating in a report on Friday, December 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Hold and an average price target of $5.55.

NASDAQ CRVS opened at $2.25 on Tuesday. The firm has a market cap of $104.73 million, a PE ratio of 37.50 and a beta of 0.87. Corvus Pharmaceuticals has a one year low of $1.86 and a one year high of $9.54. The firm’s fifty day moving average is $3.03 and its two-hundred day moving average is $3.31.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Sunday, October 31st. The company reported ($0.24) EPS for the quarter, meeting analysts’ consensus estimates of ($0.24). Research analysts anticipate that Corvus Pharmaceuticals will post -0.98 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. CHI Advisors LLC lifted its holdings in shares of Corvus Pharmaceuticals by 5.9% in the second quarter. CHI Advisors LLC now owns 719,132 shares of the company’s stock valued at $1,920,000 after purchasing an additional 40,000 shares in the last quarter. Lindbrook Capital LLC purchased a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at about $68,000. State Street Corp purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at about $79,000. Geode Capital Management LLC lifted its holdings in shares of Corvus Pharmaceuticals by 27.4% in the second quarter. Geode Capital Management LLC now owns 189,541 shares of the company’s stock valued at $506,000 after purchasing an additional 40,707 shares in the last quarter. Finally, Natixis lifted its holdings in shares of Corvus Pharmaceuticals by 69.1% in the second quarter. Natixis now owns 27,900 shares of the company’s stock valued at $74,000 after purchasing an additional 11,400 shares in the last quarter. 77.05% of the stock is currently owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors.

Featured Story: Put Option Volume

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.